Latest Manufacturing Processes News

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.

Metal Powder Works Limited (MPW) has landed a $1 million contract with the US Navy for its innovative expeditionary DirectPowder™ unit, while expanding its alloy portfolio and customer base amid a $15 million capital raise.

AML3D has landed a $4.5 million contract to supply two custom ARCEMY metal 3D printing systems to Newport News Shipbuilding, marking a significant expansion in the US defense manufacturing sector.

Provaris Energy has launched a Robotics Innovation Centre in Norway, marking a pivotal step in fabricating and testing advanced hydrogen and liquid CO2 storage tanks. The initiative aims to accelerate prototype completion and commercial scalability by early 2026.

Archer Materials has achieved critical milestones in its carbon-based quantum technology, including wafer-scale synthesis and reproducible device performance, setting the stage for operational qubits by mid-2026.

Aurora Labs has secured over A$900,000 in contracts with the Australian Defence Force, pushing forward its advanced propulsion systems and additive manufacturing capabilities. A strategic partnership with Sovereign Propulsion Systems aims to integrate these innovations into next-generation unmanned aerial systems.

Mesoblast Limited reports a robust 66% increase in Ryoncil revenues for Q2 2025, driven by strong market adoption and new Medicare reimbursement codes.

NOVONIX has delivered its first commercial-grade synthetic graphite sample at mass production scale, marking a key step toward expanding its battery and industrial materials footprint.

ClearVue Technologies has unveiled its Gen3 Solar Vision Glass, achieving a 66% increase in energy output and a 50% reduction in production time and costs, validated by independent testing. This breakthrough positions the company for accelerated commercial adoption in solar-integrated building materials.

Cambium Bio has struck a licensing deal with Keke Medtech to commercialise its fibrin biologic in dental applications, unlocking new markets and non-dilutive funding.

Papyrus Australia has marked significant progress in July 2025 with successful testing at its Rapid Prototyping facility and advancing plans for a commercial production site, while also writing down key investments.

Nanollose Limited reported a $1.43 million loss for FY2025 while progressing pilot production of innovative biomaterials and strengthening its balance sheet with a $2.1 million capital raise. The company appointed a new CEO to drive commercialisation efforts in FY2026.